As a core frontier in modern biopharmaceuticals, antibodies and Antibody-Drug Conjugates (ADCs) have emerged as critical breakthroughs in the treatment of major diseases—such as cancer and autoimmune disorders—thanks to their highly specific targeting capabilities and potent cytotoxic effects. Begelang provides comprehensive process equipment solutions spanning the entire workflow: from cell culture, antibody expression, and protein purification to ADC conjugation and purification. Through high-precision, high-stability systems, we ensure the activity, purity, and conjugation efficiency of antibody-based therapeutics. Our technologies cover the complete lifecycle of development and manufacturing for monoclonal antibodies, bispecific antibodies, and ADCs, empowering our clients to achieve their industrial objectives of delivering precision medicine, minimizing toxic side effects, and enhancing therapeutic efficacy.